GlassScriptPhysician profile
George Thomas Budd
NPI 1457315673
$21,512.76
in general payments reported to CMS, 2019-2025
10 companies · $5,636 in 2025
The $5,636 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,924 · 2022: $5,233 · 2023: $4,489 · 2024: $230 · 2025: $5,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,198 · Honoraria: $3,520 · Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,197.50 |
| Honoraria | $3,520.00 |
| Food and Beverage | $638.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $8,124.28 | 2021-2024 | Qinlock |
| Gilead Sciences, INC. | $4,398.34 | 2021-2025 | Trodelvy |
| Aadi Bioscience, INC. | $3,654.56 | 2023 | Fyarro |
| Pfizer INC. | $2,873.88 | 2025 | |
| Daiichi Sankyo INC. | $1,546.19 | 2025 | Datroway, Enhertu |
| Genentech, INC. | $750.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $165.51 | 2023-2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Budd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.